-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Incorporating Mutational Data and MRD Assessments into Treatment Decisions for Transplant-Ineligible Patients

Program: Education Program
Session: AML M&Ms: How to Integrate Mutations and MRD Data
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Diseases, Myeloid Malignancies
Saturday, December 7, 2024, 9:30 AM-10:45 AM

Courtney D. DiNardo, MD, MSc

MD Anderson Cancer Center, Houston, TX

Disclosures: DiNardo: AstraZeneca: Honoraria; Jazz: Consultancy, Honoraria; Amgen: Consultancy; Astellas: Consultancy, Honoraria; Genetech: Honoraria; Astex: Research Funding; ImmuneOnc: Research Funding; Gilead: Consultancy; Cleave: Research Funding; Servier: Consultancy, Honoraria, Other: meetingsupport, Research Funding; BMS: Consultancy, Honoraria, Research Funding; GenMab: Consultancy, Honoraria, Other: data safety board; GSK: Consultancy, Honoraria; Immunogen: Honoraria; Schrodinger: Consultancy, Honoraria; Riegel: Honoraria; Notable Labs: Honoraria; Foghorn: Research Funding; Loxo: Research Funding; Rigel: Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Stemline: Consultancy.

See more of: AML M&Ms: How to Integrate Mutations and MRD Data
See more of: Education Program
<< Previous Presentation | Next Presentation